#EUA cooling off period was due, although it's not nice seeing negative commentary, some driven by shorting, some by enmity. For the former - there are ways of shorting without being aggressive - @Smudgedann@Blowster85 proved this. For the latter - celebrate, it's great for AIM!
Onto #EUA: both interviews have been terrific. The interviewees could not have been more clear that Monch at the very least will be acquired in the near term.
- Pd has in the past 24 hours hit another ATH. Demand from auto industry is rocketing and supply pipeline is negligible.
- #EUA is the only viable UK listed Co left that offers direct exposure to Pd. A lot of cross ramping flying about on Twitter and BBs about other PGM players. I don't want direct exposure to primarily Pt plays - the market dynamics aren't appealing. Pd, however...
- The contract with Sino has been put on hold. #EUA could commence work there at any time, as the contract is binding - and thus be in receipt of the $50m subcontract. They have paused it as potential buyers might want to use other EPC providers. That's a huge show of confidence.
- Precedent transactions in the Pd space are significant. Given the dearth of independent Pd projects, premiums are being paid. Hence two investment banks signing up with #EUA - on a no win, no fee basis - to sell the assets. They're evidently confident in a successful outcome.
- Site visits have been going on for weeks. Lesego Platinum is one named suitor, but #EUA mgmt. stated in interview: "we are in discussions with.. some others", and in the RNS that it's in "ongoing negotiations".
Mgmt. can't sell on this 'spike' - they'll be aiming for higher.
It's understandable why some are calling it a P&D, the obvious question being, why would someone pay 10x for what #EUA was valued at only last week? The answer is, as I've written of extensively in the past, that AIM is an extremely inefficient market. Just look at #RRE#MKA#HZM
#EUA's extreme undervaluation has gone unnoticed owing to:
- region of operation - many won't touch Russia;
- Pd - a relatively obscure metal with a small market means that many missed the steady rally in the price;
- Glacial pace of development at Monch over past 15 years.
People see a 500% rise and automatically assume it's a P&D. I have named 3 stocks above where, if they rose 500% now, many would think they're fairly valued.
Many struggle to adapt their opinions on stocks. The big sell sign put out by #EUA should catalyse an opinion change.
Mgmt is fatigued. It's been developing its assets for many years. Monch is now permitted (a long-winded process in Russia, as #EUA has learnt the hard way!) and construction ready. This has coincided perfectly with the Pd price explosion.
No wonder mgmt is seeking to cash in.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
There are many stale holders who have been underwater for 18+ months, who will be happy to take some cash out now, in this ongoing cost of living crisis. That is understandable.
There will also be traders exiting, having positioned for this update.
Furthermore, the...
2/20
...wider investment community has not yet heard of, and even more so not appreciated the significance of, today's news at #AVCT.
Finally, I will state with a high degree of confidence that today's RNS opens the floodgates for numerous more updates in the near future.
Volume returning really nicely to the small cap space, which is creating excellent trading conditions.
My average holding period in the Short-term Trading Portfolio is still around 16 sessions / 3 weeks.
Seemingly contrary to many, I consider trade entries based both on..
2/18
...fundamentals (see two recent successful trades in MMAG and SPEC, with rationales for trades founded on earnings metrics), and on stories and associated sentiment (BSFA being most recent example).
I don't subscribe to only utilizing one or the other; the same way as I...
@AnEarlofWisdom Hi Earl, I can't see any of the posts, as I'm blocked by those accounts (or I've blocked!), but I've been told there's a lot of scaremongering about various things:
1) Delay in trial; 2) Dox not activating much in TME; 3) Low cash balance, and thus possible placing coming.
1/8
@AnEarlofWisdom On the contrary, except for Cohorts 1 and 2 taking longer than expected (due to patient withdrawals - nothing whatsoever to do with #AVA6000 itself), #AVCT's progress in 2022 could not be stronger.
The DE to 200mg/m2 was the ultimate target, so that nullifies point 2) ⬆️.
2/8
@AnEarlofWisdom Licensing deals for targeted oncology drugs - even those at pre-clinical stage, like 3996 - have been monstrous in recent times (e.g. $100m cash upfront for an antibody-drug conjugate, just last month ⬇️).
...substrate to FAP is so high that the concentration ratio of active doxorubicin in the tumour : healthy tissue, will negate the requirement for increase in dose size. [My view!]
Enough dox is already becoming active in the tumour micro-environment, at the current...
3/8
$SGEN specializes in antibody-drug conjugates ('ADC') - a relatively novel form of targeted cancer treatment.
@avacta's targeted cancer treatment platform, preCISION, has the real potential of generating pro-chemotherapies that are MORE targeted than ADCs, and thus...
2/6
...also potentially capable of delivering a more potent drug payload.
#AVCT will be announcing the results of the first preCISION prodrug P1 trial (AVA6000) in the next few months.
Success will mean the platform could be used to modify many other existing chemotherapies.
3/6